These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37338729)

  • 1. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
    Martín M; Carrasco E; Rodríguez-Lescure Á; Andrés R; Servitja S; Antón A; Ruiz-Borrego M; Bermejo B; Guerrero Á; Ramos M; Santaballa A; Muñoz M; Cruz J; Lopez-Tarruella S; Chacón JI; Álvarez I; Martínez P; Miralles JJ; Polonio Ó; Jara C; Aguiar-Bujanda D
    Breast Cancer Res Treat; 2023 Sep; 201(2):151-159. PubMed ID: 37338729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
    Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
    JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
    Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
    Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
    Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
    J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study.
    Magnoni F; Corso G; Maisonneuve P; Bianchi B; Accardo G; Sangalli C; Massari G; Rotili A; Nicosia L; Pesapane F; Montagna E; Mazzarol G; Galimberti V; Veronesi P; Curigliano G
    EClinicalMedicine; 2024 May; 71():102552. PubMed ID: 38545425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    Royce M; Osgood C; Mulkey F; Bloomquist E; Pierce WF; Roy A; Kalavar S; Ghosh S; Philip R; Rizvi F; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    J Clin Oncol; 2022 Apr; 40(11):1155-1162. PubMed ID: 35084948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
    Ruíz-Borrego M; Guerrero-Zotano A; Bermejo B; Ramos M; Cruz J; Baena-Cañada JM; Cirauqui B; Rodríguez-Lescure Á; Alba E; Martínez-Jáñez N; Muñoz M; Antolín S; Álvarez I; Del Barco S; Sevillano E; Chacón JI; Antón A; Escudero MJ; Ruiz V; Carrasco E; Martín M;
    Breast Cancer Res Treat; 2019 Aug; 177(1):115-125. PubMed ID: 31152327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study.
    Johnston SRD; Rugo HS; Tolaney SM; Munoz Fernandez M; Wei R; Martin M
    Future Oncol; 2024; 20(28):2037-2048. PubMed ID: 39023253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
    Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey EJ
    Farm Hosp; 2024; 48(2):T75-T78. PubMed ID: 38114413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
    Nelson DR; Brown J; Morikawa A; Method M
    PLoS One; 2022; 17(2):e0264637. PubMed ID: 35213669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
    Dieci MV; Conte P; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Sarti S; Ferro A; Piacentini F; Maiorana A; Orvieto E; Sanders M; Miglietta F; Balduzzi S; D'Amico R; Guarneri V
    Ann Oncol; 2019 Mar; 30(3):418-423. PubMed ID: 30657852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
    Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey Emilio J
    Farm Hosp; 2024; 48(2):75-78. PubMed ID: 37735004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
    Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N
    Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
    Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
    Fehrenbacher L; Cecchini RS; Geyer CE; Rastogi P; Costantino JP; Atkins JN; Crown JP; Polikoff J; Boileau JF; Provencher L; Stokoe C; Moore TD; Robidoux A; Flynn PJ; Borges VF; Albain KS; Swain SM; Paik S; Mamounas EP; Wolmark N
    J Clin Oncol; 2020 Feb; 38(5):444-453. PubMed ID: 31821109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.